Syneos Health Signs Agreement with Aotearoa Clinical Trials, Further Expanding Catalyst Site Program in New Zealand

MORRISVILLE, N.C. – August  10, 2023 – Syneos Health® (Nasdaq:SYNH) a leading fully integrated biopharmaceutical  solutions organization, today announced that it has signed an agreement with Aotearoa Clinical Trials, expanding the Company’s clinical trial capabilities across  a broad range of therapeutic areas in New Zealand, including Oncology, General  Medicine and Vaccines.

Aotearoa Clinical Trials now joins the Syneos Health Catalyst Site Program, which was  introduced in 2016 to strengthen collaborations with clinical research sites  worldwide.  The Program harnesses insights  from sites across the globe to drive continuous improvement and develop best  practices in clinical research delivery.

Together, Syneos Health and Aotearoa Clinical Trials will  enable sites, sponsors and patients to collaborate in multiple therapeutic  areas, fueling engagement through transparent communication channels during the  entire clinical trial process.

“Our work with Aotearoa Clinical Trials  enables us to provide customized solutions that address our customers’ unique  and complex needs,” said Dr. Ken J. Lee, General Manager and Regional Head,  Clinical Development, APAC, Syneos Health. “We look forward to collaborating  with Aotearoa Clinical Trials as part of the Catalyst Site Program.”

Syneos Health has relationships with more than 100  Catalyst sites worldwide and the Company has been acknowledged by the Society  for Clinical Research Sites as a recipient of the Eagle Award for demonstrating  dedication to establishing strong site partnerships.

Dr. Edward Watson CEO at  Aotearoa Clinical Trials welcomed the  signature of the agreement: “We are excited to be part of the Catalyst Site  Program which will enable more clinical trials to be performed in New Zealand  and provide more options for clinical trial participation  in our communities.”

About Syneos Health
Syneos Health® (Nasdaq:SYNH) is a leading fully integrated  biopharmaceutical solutions organization built to accelerate customer success.  We translate unique clinical, medical affairs and commercial insights into  outcomes to address modern market realities.  

We bring together a talented team of  professionals, who work across more than 110 countries, with a deep  understanding of patient and physician behaviors and market dynamics. 

Together we share insights, use the latest technologies and apply advanced  business practices to speed our customers’ delivery of important therapies to  patients. 

Syneos Health supports a diverse,  equitable and inclusive culture that cares for colleagues, customers, patients,  communities and the environment.  

To learn more about how we are Shortening the  distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.

About Aotearoa Clinical Trials
Aotearoa Clinical Trials  Trust is an independent charitable trust that specializes in running both  commercial (Phase I to III) and grant funded trials (investigator initiated and  collaborative group trials) in partnership with public hospitals in New  Zealand. Aotearoa Clinical Trials has over 20 years of experience as an  integrated specialist clinical trial site, which produces high quality data in  collaboration with hospital clinicians across multiple therapeutic areas.

Aotearoa Clinical Trials  aims to reduce inequity in healthcare to communities of Aotearoa - New Zealand,  by providing access of global innovative therapies through clinical trials.

Syneos Investor Relations Contact:  Ronnie Speight Senior Vice President, Investor Relations +1 919 745 2745 [email protected]

Syneos Press/Media Contact: Gary Gatyas Executive Director, External Communications +1 908 763 3428  [email protected]